{"id":821922,"date":"2025-04-23T14:32:01","date_gmt":"2025-04-23T12:32:01","guid":{"rendered":"https:\/\/businesstech.co.za\/news\/?p=821922"},"modified":"2025-04-23T14:32:06","modified_gmt":"2025-04-23T12:32:06","slug":"south-african-pharmaceutical-giant-hit-by-concerning-news","status":"publish","type":"post","link":"https:\/\/businesstech.co.za\/news\/business\/821922\/south-african-pharmaceutical-giant-hit-by-concerning-news\/","title":{"rendered":"South African pharmaceutical giant hit by concerning news"},"content":{"rendered":"\n

Aspen\u2019s share price plummeted by 30% after it warned shareholders that its earnings could significantly decline due to a material contractual dispute.<\/p>\n\n\n\n

Aspen, based in uMhlanga, South Africa, is a global speciality and branded pharmaceutical company with a presence in emerging and developed markets.<\/p>\n\n\n\n

It was founded in 1997 by Stephen Saad and Gus Attridge as a small business in an old Victorian house in Durban. Since then, it has grown tremendously.<\/p>\n\n\n\n

Today, Aspen is the largest manufacturer of generic medicines in the southern hemisphere, supplying generic medicines to over 150 countries.<\/p>\n\n\n\n

It is the first company on the continent to launch a generic anti-retroviral for the treatment of HIV and AIDS patients, thus becoming the largest supplier.<\/p>\n\n\n\n

Its share price increased by over 10,000% between 2000 and 2015, making it one of the best-performing shares on the Johannesburg Stock Exchange (JSE).<\/p>\n\n\n\n

However, the company\u2019s share price has not performed well since then. It is down significantly from its highs, and recent news saw its share price decline further.<\/p>\n\n\n\n

On Tuesday, 4 April 2025, after the market closed, it informed shareholders that \u201crisks have recently arisen relating to Aspen’s Manufacturing business\u201d.<\/p>\n\n\n\n

These risks include a material contractual dispute related to a manufacturing and technology agreement with a contract manufacturing customer for mRNA products.<\/p>\n\n\n\n

It could not provide further information, as the dispute details are subject to contractual confidentiality. However, it warned that the impact is material.<\/p>\n\n\n\n

Aspen alerted shareholders that normalised EBITDA from the Manufacturing business for the 2025 financial year in constant exchange rate could be R2 billion lower than last guided.<\/p>\n\n\n\n

Depending on the outcome of the dispute, the manufacturing business’s EBITDA for the 2025 financial year could be less than 50% of that reported in the 2024 financial year.<\/p>\n\n\n\n

In addition to these effects, an impairment of R770 million regarding related technology could also arise in the 2025 financial year.  <\/p>\n\n\n\n

Due to possible variable outcomes, Aspen said it was too early to estimate the full financial effects on the 2026 financial year and future years.<\/p>\n\n\n\n

The company will undertake mitigating activities and continue to address the dispute. \u201cShareholders will be updated on any related developments as and when appropriate,\u201d it said.<\/p>\n\n\n\n

Aspen affected by the United States’ trading changes<\/h2>\n\n\n\n
\"\"<\/a>
Aspen CEO Stephen Saad<\/figcaption><\/figure>\n\n\n\n

Aspen said the pharmaceutical industry has been, and will continue to be, affected by the current turbulent and unpredictable world trading environment.<\/p>\n\n\n\n

\u201cThose who sell products in the United States are likely to source them from manufacturing sites within the country,\u201d it said.<\/p>\n\n\n\n

Other countries and continents have also been impacted as health security and independence have become a greater priority.<\/p>\n\n\n\n

This shifting landscape provides both risk and opportunity for Aspen\u2019s contract manufacturing business.<\/p>\n\n\n\n

\u201cAspen has valuable and needed manufacturing capacities and skills to assist in filling voids that have become evident in the changing global pharma landscape,\u201d it said.<\/p>\n\n\n\n

\u201cWe will work to reposition Aspen for the new opportunities which present themselves in this fluid environment.\u201d<\/p>\n\n\n\n

In a live webcast on 23 April 2025, Aspen CEO Stephen Saad said the pharmaceutical industry is highly exposed to the risk in the current global environment.<\/p>\n\n\n\n

\u201cWe expect to be exposed to tariffs imposed by the United States and the retaliatory tariffs imposed by other countries,\u201d he said.<\/p>\n\n\n\n

He said the threat of tariffs has already significantly impacted the industry, and countries will need to consider health independence.<\/p>\n\n\n\n

Although the confidentiality clause prevented him from discussing the contractual dispute in detail, he said it was unexpected.<\/p>\n\n\n\n

\u201cThis development is a bitter disappointment, exacerbated by the value of the investment we made to access the mRNA technology,\u201d Saad said.<\/p>\n\n\n\n

Aspen has two mRNA facilities \u2013 one in France and another in South Africa. This dispute will impact both facilities.<\/p>\n\n\n\n

He added that although it will take time, Aspen will replace any business that it may lose due to this contractual dispute.<\/p>\n\n\n\n

Negative market reaction<\/h2>\n\n\n\n

The market did not like the news, and the Aspen share price plummeted by over 30% on Wednesday, 23 April 2025.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

Aspen\u2019s share price plummeted by 30% after it warned shareholders that its earnings could significantly decline due to a material contractual dispute.<\/p>\n","protected":false},"author":10,"featured_media":821929,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9872],"tags":[13435,21892],"class_list":["post-821922","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-aspen","tag-stephen-saad"],"_links":{"self":[{"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/posts\/821922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/comments?post=821922"}],"version-history":[{"count":4,"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/posts\/821922\/revisions"}],"predecessor-version":[{"id":821931,"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/posts\/821922\/revisions\/821931"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/media\/821929"}],"wp:attachment":[{"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/media?parent=821922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/categories?post=821922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/businesstech.co.za\/news\/wp-json\/wp\/v2\/tags?post=821922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}